What started out as shoulder pain turned into a living nightmare for a Melbourne girl and her family after doctors discovered a large mass in the eight-year-old’s chest, which turned out to be a rare ...
CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...
Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for ...
A fasting-derived ketone metabolite reshapes CAR T cell metabolism and gene activity, boosting immune cell expansion, energy ...
Detailed price information for Citius Pharmaceuticals Inc (CTXR-Q) from The Globe and Mail including charting and trades.
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius ...
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), ...
After weeks of doctor visits and her condition worsening, Emma Operacz was given an unexpected diagnosis ...
Topline data of investigator-initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response ...
The Kathmandu Post on MSN
Nepal approves first domestically produced CAR T-cell therapy
Kathmandu, March 7 -- Nepal has approved its first domestically manufactured CAR T-cell therapy for clinical use, marking a milestone in the country's cancer treatment capabilities. The Department of ...
Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) (stock code: 7427) announced that its independently developed novel epigenetic immunoactivator GNTbm-38, with global rights for cancer ...
The biotech company secured investigational new drug clearance from US regulators to begin human testing of its GNTbm-38 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results